Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

被引：0
|
作者：
Chao Jing
Junyun Wang
Mingyue Zhu
Zhigang Bai
Baoyi Zhao
Jun Zhang
Jie Yin
Xiaobao Yang
Zongzhi Liu
Zhongtao Zhang
Wei Deng
机构：
[1] Beijing Friendship Hospital,Department of General Surgery, Medical Oncology Group
[2] Capital Medical University,CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics
[3] Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases,Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital
[4] Chinese Academy of Sciences/China National Center for Bioinformation,undefined
[5] Chinese Academic of Medical Sciences and Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Immune checkpoint inhibitors; Molecular targeted therapy; Camrelizumab; Apatinib; Advanced gastric cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2597 / 2608
页数：11
相关论文
共 50 条
  • [21] Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
    Wang, Yakun
    Wang, Chang
    Chen, Xiaofeng
    Peng, Zhi
    Gu, Yanhong
    Wang, Yizhuo
    Wang, Xicheng
    Li, Jian
    Gong, Jifang
    Qi, Changsong
    Yuan, Jiajia
    Lu, Zhihao
    Lu, Ming
    Shen, Lin
    Cao, Yanshuo
    Zhang, Xiaotian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 351 - 351
  • [22] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
    Chen, Xiaofeng
    Xu, Hao
    Wang, Deqiang
    Chen, Xiaobing
    Wang, Kangxin
    Jin, Guangfu
    Ding, Yongbin
    Tang, Jie
    Fang, Yueyu
    Sun, Hui
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    Guo, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 365 - 365
  • [23] Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study.
    Zou, Zhengyun
    Zhao, Lianjun
    Ren, Yu
    Sha, Huizi
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
    Miaomiao Gou
    Yong Zhang
    Zhikuan Wang
    Niansong Qian
    Guanghai Dai
    Investigational New Drugs, 2024, 42 : 171 - 178
  • [25] PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study
    Gou, Miaomiao
    Zhang, Yong
    Wang, Zhikuan
    Qian, Niansong
    Dai, Guanghai
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 171 - 178
  • [26] Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
    Yao, Yiwei
    Wang, Yong
    Du, Yingying
    Jiang, Fengshou
    Liang, Hui
    Bi, Minghong
    Xie, Hua
    Peng, Wanren
    Pan, Yueyin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 125
  • [27] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose-escalation and expansion study.
    Chen, Xiaofeng
    Ding, Yongbin
    Wang, Deqiang
    Wang, Kangxin
    Xu, Hao
    Tang, Jie
    Li, Wei
    Fang, Yueyu
    Sun, Hui
    Liu, Liang
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16053 - E16053
  • [28] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [29] Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
    Jin Li
    Shukui Qin
    Lu Wen
    Junsheng Wang
    Wenying Deng
    Weijian Guo
    Tongfu Jia
    Da Jiang
    Guifang Zhang
    Yifu He
    Yi Ba
    Haijun Zhong
    Lin Wang
    Xiaoyan Lin
    Jianwei Yang
    Jun Zhao
    Yuxian Bai
    Xiangyuan Wu
    Feng Gao
    Guogui Sun
    Yongjuan Wu
    Feng Ye
    Qiong Wang
    Zhong Xie
    Tienan Yi
    Yong Huang
    Guohua Yu
    Lin Lu
    Ying Yuan
    Wei Li
    Likun Liu
    Yuping Sun
    Ying Sun
    Lifeng Yin
    Zhiguo Hou
    BMC Medicine, 21
  • [30] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Zhaoqing Tang
    Yan Wang
    Yiyi Yu
    Yuehong Cui
    Liang Liang
    Chen Xu
    Zhenbin Shen
    Kuntang Shen
    Xuefei Wang
    Tianshu Liu
    Yihong Sun
    BMC Medicine, 20
12345